Blog/News

Cell Therapy Supply Chain With 1920 ongoing clinical trials as of Q4 2023, the pipeline for new therapies is rich in diversity of diseases under investigation and is continuing to grow. A major follow-on question is whether the gene and cell therapy . . .
Robust pipeline demonstrated at Advanced Therapies Week 2024 As we reflect on the monumental strides made in 2023 within the field of cell and gene therapy, Advanced Therapies Week 2024 served as an inspiring launchpad for the year ahead. Groundbrea . . .
Strategic Partnership With Vitalant to Bring Better Therapies to Patients Partnership to deliver enhanced donor profiles for higher potency cell therapeutics SAN DIEGO. CA, January 17, 2024, – Excellos Inc., a cell therapy contract and developme . . .
TC BioPharm Selects Excellos as CDMO in Anticipation of Expanded US Clinical Trial Requirements EDINBURGH, Scotland, Oct. 25, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechno . . .
June 27, 2023; San Diego, California – Excellos Opens Cutting-Edge Cell Therapy GMP Manufacturing Facility in Downtown San Diego. Cell Therapy GMP Manufacturing Facility Excellos, a full-service contract development and manufacturing organizatio . . .
The central aims of Excellos 360 are to reduce clinical response variability and possibly improve outcomes, lower safety liability by allowing effectiveness in lower dosages and reducing the cost of goods associated with advanced therapies. Januar . . .
In a recent publication [1], a collaborative research group based in La Jolla, CA cite using Excellos sourced T cells to discover cell subset-based links to disease risk by using single-cell analysis. The La Jolla researchers are studyin . . .
Scientists at the University of Florida College of Medicine report that natural variability in donor stem cells can have a dramatic impact on the transduction efficiency of vector-delivered cell and gene therapy products. [1] Gene therap . . .
CHARLOTTE, N.C. and SAN DIEGO, Oct. 26, 2022 /PRNewswire/ -- Barings, one of the world's largest diversified real estate investment managers, along with Phase 3 Real Estate Partners and Bain Capital Real Estate, announced today that their joint ven . . .
Researchers at the La Jolla Institute for Immunology cite using Excellos sourced healthy donor starting material to carry out single-cell immune profiling for their research on severe COVID-19. [1] The purpose of the study was to identify wh . . .
A case of immune T cell identity theft (trogocytosis) gave German scientists the vital clue they needed to understand a key mechanism behind the development of multiple sclerosis (MS). In a recently published paper, scientists at the Institute of . . .
Scientists at Scripps Research Center in La Jolla are working to streamline monoclonal antibody vaccine development by devising more efficient ways to screen for rare B antigen-specific B cells. [1] Today, monoclonal antibodies (mAbs) are at . . .
Researchers at UCSD and Memorial Sloan Kettering Cancer Center used Excellos healthy donor starting material to carry out a fascinating study on ultrasonic activation of cancer immunotherapy. CAR-T cell therapy is a paradigm shifting therape . . .
NK cell therapy holds the promise of new therapeutics for underserved cancer indications. A recent publication in Nature Communications uses Excellos sourced cellular starting materials for research on the mechanisms behind NK cell cytotoxicity. [1 . . .
A new Allogeneic CAR-T study has shown CAR-T cells derived from healthy donors to be superior at fighting cancer compared to CAR-T cells derived from patients. [1] In a press release, biotechnology company Allogene Therapeutics announced pre . . .
Where the Cell Therapy industry is facing an ever-growing complexity in supply chain and logistics, now is the time to optimize the cell therapy supply chain to create a dependable supply of cellular therapeutics. Adam Clark, Director of Commercial . . .
Raw material experts Dr. David Wellis and Dr. Robert Tressler want to share their knowledge on how to select and source cellular starting materials that build the foundations of successful cell therapies. Dr. Wellis and Dr. Tressler are . . .
Next-level donor immune cell characterization can be used as a foundation for promoting high patient response rates. Last week in Part 1 of our donor characterization series, we dove into T cell function and donor immune cell characterizatio . . .
Donors play an important role in how well patients respond to immunotherapy, making donor characterization a critical success factor. Chimeric antigen receptor (CAR) T cell therapy has shown very promising results, helping leukemia and lymphoma . . .
Scientists at the H. Lee Moffitt Cancer Center in Florida are investigating the potential for using tumor infiltrating lymphocytes (TIL therapy) in the fight against metastatic lung cancer. [1] PD-1 immune checkpoint inhibitors and CAR T cel . . .
Scientists at GSK in Waltham, Massachusetts, are using Excellos-sourced T cell starting material for their preclinical evaluation of an anti-PD1 antibody. Programmed Cell Death Protein-1 (PD-1) is a transmembrane protein recognized for its r . . .
As Dan Stanton covered in BioProcess International last week(1) , and Jayne Bryne addressed in BioPharma Reporter(2), the launch of Excellos now brings scientific and cell manipulation expertise to support the development of investigational cell th . . .
T cell immunotherapy is a promising and relatively new field of medicine focused on tailoring a person’s own immune cells to fight disease more effectively. The field has enjoyed early success in the area of cancer immunotherapy, most notably the . . .
Founded by an Experienced Management Team and Built on the Reach and Infrastructure of the San Diego Blood Bank Cell and Gene Therapy CDMO San Diego, CA: Excellos, Incorporated, a cell therapy Contract Development and Manufacturing Organiza . . .